After back-to-back sessions of gains, the shares of Cassava Sciences (SAVA -3.0%) fell today as social media buzz renewed the concerns over the company’s research conduct for investigational Alzheimer’s therapy simufilam.
Full Answer
Why is cassava Sciences (Sava) stock falling?
Cassava Sciences (NASDAQ: SAVA) stock is falling on Tuesday as investors react to a recent fireside chat from CEO Remi Barbier. Cassava Sciences has been hit or miss with investors as turmoil surrounds its clinical trial results.
Will cassava Sciences' Alzheimer's disease treatment sway the stock market?
On March 16, our two most experienced analysts will reveal what’s coming next in the stock market and share two FREE stock recommendations that could soar during these uncertain times. Allegations about Cassava Sciences' Alzheimer's disease treatment have SAVA stock falling today
Will cassava Sciences stock outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe SAVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Cassava Sciences does not currently pay a dividend. Cassava Sciences does not have a long track record of dividend growth.
How much of cassava Sciences'stock is owned by institutions?
Only 29.68% of the stock of Cassava Sciences is held by institutions. Earnings for Cassava Sciences are expected to grow in the coming year, from ($0.87) to ($0.20) per share.
Why is cassava Sciences stock down today?
Cassava Sciences (NASDAQ:SAVA) stock is falling on Tuesday as investors react to a recent fireside chat from CEO Remi Barbier. Cassava Sciences has been hit or miss with investors as turmoil surrounds its clinical trial results.
Will cassava stock go back up?
Cassava Sciences Inc quote is equal to 29.040 USD at 2022-06-04. Based on our forecasts, a long-term increase is expected, the "SAVA" stock price prognosis for 2027-05-28 is 58.096 USD. With a 5-year investment, the revenue is expected to be around +100.05%. Your current $100 investment may be up to $200.05 in 2027.
Is Cassava stock a good buy?
Cassava Sciences's analyst rating consensus is a 'Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
Why did SAVA drop so much?
Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US)....Performance Outlook.Previous Close27.56Volume1,657,336Avg. Volume1,690,2765 more rows
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 31.50, with a high estimate of 82.78 and a low estimate of 23.03. The median estimate represents a +54.92% increase from the last price of 20.33.
Who owns SAVA?
Largest shareholders include BlackRock Inc., Vanguard Group Inc, State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, LMR Partners LLP, Susquehanna International Group, Llp, IWM - iShares Russell 2000 ETF, Susquehanna International Group, Llp, Citadel Advisors Llc, and Citadel Advisors Llc ...
Should I sell my cassava Sciences stock?
The consensus among Wall Street research analysts is that investors should "hold" Cassava Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
Why is Sava going up?
Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US)....Performance Outlook.Market Cap1.067B1y Target Est92.506 more rows
Is Sava buy or sell?
The consensus among 2 Wall Street analysts covering (NASDAQ: SAVA) stock is to Strong Buy SAVA stock.
What are squeeze stocks?
A short squeeze is an unusual condition that triggers rapidly rising prices in a stock or other tradable security. For a short squeeze to occur, the security must have an unusual degree of short sellers holding positions in it. The short squeeze begins when the price jumps higher unexpectedly.
What does Cassava Sciences do?
Cassava Sciences, Inc. operates as a clinical-stage biotechnology company. The Company detects and treats neurodegenerative diseases such as alzheimer's. Cassava Sciences serves clients in the United States.
Is Cassava Sciences a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rat...
When is Cassava Sciences' next earnings date?
Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Cass...
How were Cassava Sciences' earnings last quarter?
Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings data on Thursday, May, 5th. The company reported ($0.44) EPS for the quarter, mi...
When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?
Cassava Sciences shares reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of share...
What price target have analysts set for SAVA?
5 brokerages have issued 12 month price targets for Cassava Sciences' stock. Their forecasts range from $58.00 to $215.00. On average, they anticip...
Who are Cassava Sciences' key executives?
Cassava Sciences' management team includes the following people: Mr. Remi Barbier , Founder, Chairman, Pres & CEO (Age 62, Pay $1.74M) Mr. Eric...
Who are some of Cassava Sciences' key competitors?
Some companies that are related to Cassava Sciences include Cerevel Therapeutics (CERE) , Galapagos (GLPG) , Arrowhead Pharmaceuticals (ARWR) ,...
What other stocks do shareholders of Cassava Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceutic...
What is Cassava Sciences' stock symbol?
Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."
10 Most Shorted Stocks Right Now
In this article, we discuss the 10 most shorted stocks right now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Most Shorted Stocks Right Now. The beginning of 2021 had pitted retail investors against hedge funds in a short squeeze saga involving video game firm GameStop and […]
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.
Why is cassava stock so high in 2021?
Cassava's stock has skyrocketed because the company has a new approach to Alzheimer's treatment.
How much has GameStop soared in January?
When we think of this year's biggest stock market movers, GameStop probably comes to mind. GameStop soared more than 1,700% in the first few weeks of January. Cassava Sciences (NASDAQ: SAVA) has climbed about 1,120% year to date.
A public offering is weighing on the biophama's shares today
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
What happened
Shares of the clinical-stage biopharma Cassava Sciences ( NASDAQ:SAVA) dropped by a whopping 18.5% in after-hours trading Thursday. The drugmaker's stock hit the skids yesterday following the announcement of an underwritten public offering.
So what
Shareholders rarely take kindly to public offerings. In this case, however, Cassava may be doing shareholders a real solid. The long and short of it is the company simply didn't have the funds to advance sumifilam into a late-stage trial.
Now what
Shareholders, for their part, were probably hoping for a licensing deal or a straight up buyout in lieu of a capital raise. The reality, though, is that Cassava would have been negotiating from a position of weakness in either case. It wasn't a secret that the biopharma was essentially broke, after all.